CA
NZ
UK
AU
IND
US
…
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Foghorn Therapeutics is a biotechnology company developing small-molecule therapeutics that target chromatin regulatory mechanisms to treat cancer and other diseases. Its proprietary discovery platform identifies modulators of chromatin biology and the company is advancing candidates across preclinical and clinical stages, which may support long-term growth through clinical progress and partnerships.
Key risks include clinical and regulatory failure, high cash burn and future financing needs, competition from larger biopharma, and uncertainty whether platform discoveries will translate into approved therapies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -108.88M | -101.32M | -68.80M | -51.13M | -26.34M |
| Net income | -108.87M | -103.23M | -69.78M | -51.67M | -26.34M |
| Selling general administrative | 30.75M | 21.73M | 11.25M | 6.72M | 4.82M |
| Gross profit | 19.21M | 1.32M | 0.43M | - | - |
| Reconciled depreciation | 3.32M | 3.23M | 1.33M | 0.69M | 0.38M |
| Ebit | -120.46M | -100.73M | -68.53M | -51.08M | -25.94M |
| Ebitda | -117.14M | -94.95M | -66.20M | -49.90M | -25.56M |
| Depreciation and amortization | 3.32M | 5.78M | 2.33M | 1.19M | 0.38M |
| Non operating income net other | 8.26M | 1.32M | 0.71M | - | - |
| Operating income | -117.14M | -100.73M | -68.53M | -51.08M | -26.05M |
| Other operating expenses | 136.37M | 102.05M | 68.96M | 51.08M | 26.05M |
| Interest expense | 11.57M | 1.91M | 0.98M | 0.54M | 0.37M |
| Interest income | 5.67M | 2.55M | 1.00M | 0.49M | 0.11M |
| Net interest income | 5.67M | 0.65M | 0.02M | -0.04M | -0.26M |
| Income tax expense | -0.01M | 1.91M | 0.98M | 0.54M | 0.08M |
| Total revenue | 19.23M | 1.32M | 0.43M | 0.00M | 0.00M |
| Total operating expenses | 136.37M | 102.05M | 68.96M | 51.08M | 26.05M |
| Cost of revenue | 0.02M | 0.00M | - | - | - |
| Total other income expense net | 8.26M | -0.59M | -0.27M | -0.04M | -0.03M |
| Net income from continuing ops | -108.88M | -101.32M | -68.80M | -51.13M | -26.34M |
| Net income applicable to common shares | -108.88M | -101.32M | -68.80M | -51.13M | -26.34M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 285.92M | 404.88M | 519.77M | 255.59M | 22.34M |
| Other current assets | 6.12M | 5.60M | 5.27M | 4.92M | 1.36M |
| Total liab | 363.11M | 404.77M | 422.90M | 109.41M | 110.36M |
| Total stockholder equity | -77.19M | 0.11M | 96.87M | 146.19M | -88.02M |
| Other current liab | 9.11M | -11.38M | 9.56M | 9.16M | 0.45M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -471.56M | -373.14M | -264.26M | -162.94M | -94.14M |
| Other liab | - | 304.03M | 322.87M | 12.55M | - |
| Other assets | 0.00M | 4.09M | 4.13M | 2.58M | 1.74M |
| Cash | 80.34M | 345.80M | 101.14M | 92.80M | 14.98M |
| Total current liabilities | 58.44M | 336.82M | 48.69M | 18.85M | 12.65M |
| Current deferred revenue | 34.55M | 336.82M | 28.32M | 2.02M | 3.25M |
| Net debt | -35.26M | -294.29M | -42.80M | -10.80M | 1.65M |
| Short term debt | 8.52M | 5.97M | 6.99M | 3.98M | 5.51M |
| Short long term debt | - | - | - | - | 4.15M |
| Short long term debt total | 45.07M | 51.51M | 58.33M | 82.00M | 16.63M |
| Other stockholder equity | 395.20M | 377.23M | 361.13M | 53.53M | 6.12M |
| Property plant equipment | - | 49.40M | 56.08M | 62.33M | 3.71M |
| Total current assets | 240.18M | 345.80M | 459.56M | 190.69M | 16.89M |
| Net tangible assets | - | 0.11M | 96.87M | 146.19M | -88.02M |
| Short term investments | 153.72M | 293.58M | 53.15M | 92.97M | - |
| Net receivables | - | 2.38M | 300.00M | 0.84M | - |
| Long term debt | - | - | - | 19.65M | 10.96M |
| Inventory | - | - | -353.15M | - | - |
| Accounts payable | 6.26M | 5.41M | 3.82M | 3.68M | 3.44M |
| Accumulated other comprehensive income | -0.83M | -3.99M | -0.01M | -0.01M | -1.29M |
| Common stock total equity | - | 0.00M | 0.00M | 0.00M | - |
| Retained earnings total equity | - | -373.14M | -264.26M | -162.94M | - |
| Non currrent assets other | 1.11M | 9.69M | 4.13M | 2.58M | 1.74M |
| Non current assets total | 45.73M | 59.09M | 60.21M | 64.91M | 5.46M |
| Capital lease obligations | 45.07M | 51.51M | 58.33M | 62.34M | 1.52M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -243.11M | 39.49M | -108.91M | -0.96M | -1.54M |
| Change to liabilities | 3.06M | 2.79M | 15.04M | 1.21M | 1.28M |
| Total cashflows from investing activities | -244.32M | 36.17M | -108.91M | -0.96M | -1.54M |
| Net borrowings | - | -21.20M | 4.27M | 7.98M | 11.14M |
| Total cash from financing activities | 1.76M | 22.42M | 217.47M | 23.97M | 51.77M |
| Change to operating activities | -5.84M | -303.17M | 13.66M | -0.01M | 1.15M |
| Net income | -108.88M | -101.32M | -68.80M | -51.13M | -26.34M |
| Change in cash | -48.95M | 8.34M | 77.27M | -23.33M | 27.58M |
| Begin period cash flow | 102.87M | 94.53M | 17.25M | 40.59M | 13.00M |
| End period cash flow | 53.92M | 102.87M | 94.53M | 17.25M | 40.59M |
| Total cash from operating activities | 193.61M | -50.25M | -31.29M | -46.34M | -22.65M |
| Issuance of capital stock | 0.00M | 42.20M | 211.98M | 15.29M | 40.44M |
| Depreciation | 3.32M | 3.23M | 1.33M | 0.69M | 0.38M |
| Other cashflows from investing activities | - | - | 0.25M | - | - |
| Change to inventory | - | -3.17M | - | - | - |
| Change to account receivables | 300.00M | -300.00M | -300.00M | -300.00M | - |
| Sale purchase of stock | 1.76M | 43.62M | 123.34M | - | - |
| Other cashflows from financing activities | -244.32M | 1.42M | 110.88M | -0.96M | 52.59M |
| Change to netincome | 14.34M | 9.94M | 7.48M | 2.90M | 0.89M |
| Capital expenditures | 1.21M | 3.31M | 16.18M | 0.97M | 1.54M |
| Cash flows other operating | 283.07M | 34.94M | 29.24M | - | - |
| Cash and cash equivalents changes | -48.95M | 8.34M | 77.27M | - | - |
| Change in working capital | 281.55M | 33.44M | 28.70M | 1.20M | 2.42M |
| Stock based compensation | 14.34M | 8.38M | 2.96M | 1.69M | 0.73M |
| Other non cash items | 3.29M | 4.61M | 4.44M | 1.20M | 0.12M |
| Free cash flow | 192.40M | -53.56M | -47.47M | -47.30M | -24.19M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics Inc |
-0.12 5.74% |
1.97 | - | - | 9.25 | 10.71 | 3.71 | -1.21 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Adrian H. B. Gottschalk | Pres, CEO & Director | 1976 |
| Dr. Allan Reine M.D. | Chief Financial Officer | 1975 |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer | 1973 |
| Dr. Gerald R. Crabtree M.d. | Founder & Member of Scientific Advisory Board | NA |
| Dr. Steven F. Bellon Ph.D. | Chief Scientific Officer | 1965 |
| Mr. Ben Strain | VP of Investor Relations & Corp. Communications | NA |
| Mr. Michael J. LaCascia | Chief Legal Officer | 1965 |
| Mr. Saurabh Sewak Ph.D. | VP of Corp. Devel. | NA |
| Mr. Carlos Costa | Chief People Officer | NA |
| Ms. Fanny Cavalie | Chief Strategy & Bus. Operations Officer | 1978 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...